Project Details
Description
MT2019-09: A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR????+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PID
| Status | Finished |
|---|---|
| Effective start/end date | 8/16/19 → 7/31/24 |
Funding
- CHILDREN'S HOSPITAL LOS ANGELES
- NIH NATIONAL INST OF ALLERGY & INFECT DI
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.